Human porphobilinogen deaminase (PBGD), the third enzyme in the heme pathway, catalyzes four times a single reaction to convert porphobilinogen into hydroxymethylbilane.
Introduction
The linear tetrapyrrole hydroxymethylbilane (HMB, also named pre-uroporphyrinogen) is the precursor of a variety of essential metabolites including hemes, chlorophylls and cobalamin.
In particular, the heme group acts as a prosthetic addition to many enzymes, transporters, and receptors including hemoglobin, myoglobin, catalases, peroxidases, cytochromes P450, and in sensor proteins for diatomic gases such as O 2 or NO (1) . There are three pathways to make heme (2) yet, in eukaryotes, heme synthesis appears to follow the protoporphyrin pathway (3) . Heme synthesis is accomplished by the sequential action of several enzymes (eight in humans, mainly expressed in liver and in erythroid cells). Porphobilinogen deaminase (PBGD, EC 2.5.1.61) is the third enzyme of this biosynthetic route, catalysing the condensation of four units of porphobilinogen (PBG) to yield HMB, which is the precursor to all the tetrapyrroles. Inborn errors in any of these enzymes ultimately lead to severe metabolic disorders family termed as porphyrias (4) . Specifically, mutations in HMBS are responsible for Acute Intermittent Porphyria (AIP) with more than 400 pathogenic mutations described so far (including nonsense, missense and other mutations) (5, 6) .
PBGD is a monomeric enzyme, highly conserved across different species, with a molecular mass ranging between 34 to 45 kDa. ApoPBGD is thermodynamically unstable and it spontaneously and covalently attaches a dipyrromethane cofactor (DPM) from the reaction of the apo-enzyme with hydroxymethylbilane to generate the active holoenzyme in its ES 2 form (7, 8) . Human PBGD is comprised of 3 distinct domains (9) and shares over 45% primary sequence identity with its counterparts from E. coli and others (10) . Two isoforms have been reported: the 44-kDa ubiquitous (housekeeping) enzyme (PBGD1) and the 42-kDa erythrocyte-specific enzyme (PBGD2) (11) . The ubiquitous PBGD1 has 17 extra residues in the N-terminal region when compared to erythrocytic PBGD2. The role for this tail in the N-terminal region is unclear but experimental evidence demonstrates that such residues remain unstructured, do not alter the overall fold, nor the catalytic activity, nor the enzyme's stability (12) .
PBGD catalyses the formation of HMB by incorporating four units of PBG in a multistep reaction ( Fig. S1 ) (13) . Reaction initially involves deamination of the PBG, followed by the attachment of the resulting azafulvene to the free alpha position. The DPM cofactor serves as a primer for the loading of further PBG molecules and, remarkably, holoPBGD uses the same acidic residue (D99 in the human sequence) for the pyrrole condensation (four times), repeating reactions where each intermediate of the polypyrrole elongation remains covalently attached to the DPM cofactor (14) . The resulting linear hexapyrrole is unstable and cleaves off through an unknown mechanism to yield the linear tetrapyrrole HMB product, also restoring holoPBGD.
Two different mechanisms have been proposed to explain how the enzyme deals with the growing oligopyrrole chain during catalysis and how the cleavage of the product occurs (15, 16) . The first one assumes that the enzyme structure is flexible, such that the active site is opened for the entry of a new PBG molecule and closed during the ring fusion. Such opening and closing of the active site in human PBGD would be accomplished by movement of protein domains around proposed hinge regions (S96, H120, L238) (9) . The second mechanism speculates that at least four pyrroles could be accommodated without significant movement of the protein domains. Rotation of the cofactor around the covalent bond linking the methylene C atom of the C1 pyrrole with the Cys261 S atom would cause the C1 and C2 rings to vacate their respective binding sites and potentially allow another pyrrole moiety to bind at the catalytic centre of the enzyme. The cofactor movement would be aided by the presence of two almost completely invariant glycine residues (17) .
To date, 14 crystal structures of the protein are available in the Protein Data Bank (2 of H. sapiens, 5 of E. coli, 5 of B. megaterium, 1 of A. thaliana and 1 of V. cholerae) (9, 10, (17) (18) (19) (20) .
Despite these efforts, the structures are either the apo-(50V4, D82A-PBGD of B. megaterium) or the holoPBGD and they provide little information on the intermediate catalytic stages of PBGD. Here, we present crystal structures of PBGD loaded with the cofactor (E holo , 2.78 Å, PDB-ID: 5M7F) and PBGD with two additional substrate rings (ES 2 , 2.73 Å, PDB-ID: 5M6R). Our structures, supported by additional Small Angle X-ray Scattering (SAXS) and NMR experiments, allow us to propose a model for the reaction progression, with fewer enzyme structural changes than previously suggested, mostly effected by a change in volume at the active site. The latter change in turn results from a substrate-induced rearrangement of a flexible loop (R255-V263) sliding over the active site during reaction progression, in basic agreement with the static hypothesis. The large number of AIP-causing mutations occurring in this loop confirm the key relevance of this structural element not only for the reaction but also in disease.
Materials & Methods
Protein expression and purification. Freshly transformed E. coli BL21 (DE3) cells were used for protein expression. Cells to produce proteins for crystallization tests were grown in regular LB media, whereas cells to produce protein samples required for NMR experiments included ammonium chloride as the sole sources of nitrogen for protein synthesis. Protein purification was achieved as previously described (21) , with the following modifications: the fractions containing pure PBGD were then loaded to an anion exchange chromatography column, either a HiTrap Q HP 5ml or MonoQ 5/50 GL. The resulting enzyme-intermediate complexes were eluted with a linear gradient of buffer B; 0-30% in 35 CV or 0-20% in 50CV for respectively, Q or MonoQ column. Separated complexes, whose concentration were measured by UV-vis spectrometry at 280 nm, can be used immediately or flash frozen in 1 ml aliquots and stored in -80 ºC.
SAXS data collection and analysis. Synchrotron SAXS data were collected on beamline BM29 at ESRF (Grenoble, France) with a 2D detector (Pilatus 1M) over an angular range q min = 0.01 Å −1 to qmax = 0. 
Results
Isolation of human PBGD reaction intermediates. Investigation of the reaction mechanism requires the isolation of the PBGD reaction intermediates, which is a challenging task because each such species shows inherent reversibility, thus affecting the integrity of each isolated form over time. To address this issue, reaction intermediates of human PBGD (PBGD1 or PBGD2) were heterologously expressed in E. coli and purified as previously described (27) but adapting a protocol to ensure maximum purity and stability of the isolated intermediates (see Materials & Methods). Specifically, no ammonium ions were present at any time during the purification, not to shift the reaction balance to E holo ; and size exclusion chromatography was used as an early purification step, before optimizing the ion exchange chromatographic separation of the intermediates. As a result, five enzyme reaction intermediates could be isolated from each isoenzyme form, as determined by native gel analysis ( Reaction intermediates do not show large conformational changes. We have used a set of biophysical techniques to characterize the conformational changes across the PBGD reaction intermediates. First, small-angle X-ray scattering (SAXS) was collected at a synchrotron source for each of the protein intermediates (obtained from the PBGD1 isoform).
For all collected datasets, SAXS data is only compatible with a monomeric form of PBGD, in agreement with ion exchange chromatography elution profiles (Fig. S2) . The low-resolution SAXS-derived structural models were compared to the human high-resolution structure (PDB-ID: 3ECR, E holo ). To that end, the 3ECR structure was completed with homology modelling to fill the portions missing from the crystal structure (1-20, 60-78, 361-364) and subjected to the MD simulations for structure relaxation (17 ns, see Star Methods section), while the cofactor and reaction intermediates were not included. The SAXS molecular shapes (colorful mesh) are in good agreement with the 3ECR structure (black cartoon) for E holo , ES and ES 2 reaction intermediates ( Fig. 2A ). The radius of gyration (R g ), estimated
from the low-angle scattering region by a Guinier plot (28), also yields no significant differences among these enzyme variants ( Fig. 2B and Table 1 ). In case of the last stage of reaction, before product release (PBGD ES 3 ), SAXS reports a larger R g value and increases
in the maximum linear dimension D max and in the Chi parameter, but the 3ECR structure still fits the E holo SAXS-derived low-resolution envelope rather well. 
High resolution structures for E holo and the ES 2 reaction intermediate. To maximize
chances of obtaining diffraction-quality PBGD crystals, trials using both PBGD variants (PBGD1 and PBGD2) were attempted, using crystallization screens based on the conditions reported in the literature or commercially available screens. The temperature was also varied. Crystals were always grown in the dark, to prevent cofactor and substrate photooxidation and the protein concentration was finely tuned, since PBGD tends to form multiple crystal plates that grow in tight stacks (Fig. S3) . The yellow color of the crystals indicates partial oxidation of the polypyrrol moiety. Out of the more than 160 crystals tested and more than 40 diffraction datasets collected, two diffraction datasets yielded structures for two reaction intermediates: E holo (PBGD2, Fig. S4 ) and (ES 2 , PBGD1, Fig. S5 ).
The E holo and ES 2 -complex crystal structures were determined to 2.78 Å and 2.73 Å resolution, respectively. The crystallographic data collection and refinement statistics are presented in Table 2 . Both crystals belong to the monoclinic space group P2 1 Fig. 3B ). In the ES 2 structure the loop is pulled back from the active site, displacing the Cys261 covalently-linked cofactor to a novel binding site. Such rearrangement is key for understanding the mechanism of substrate elongation (vide infra) but it also underlines the fact that localized and not domain motions govern the conformational changes from E holo to ES 2 , consistent with the SAXS and NMR data.
Structure of the active site and insights into the catalytic mechanism. In the E holo PBGD structure, the dipyrromethane cofactor (pyrrole units C1 and C2, Fig. 4A ) is positioned within a deep positively charged cleft formed between domains 1 and 2 (purple and orange volumes in Fig. 4E corresponding to the frontal and rear sub-cavities of the cleft). This ligand placement is also found in equivalent E holo PBGD high-resolution structures and the cofactor is stabilized by well described interactions with surrounding residues (Fig. 4C ) (10, 18, 33) .
The C1 pyrrole unit is covalently attached to C261, which belongs to a loop (R255-V263) located in domain 3. In the ES 2 PBGD structure, the R255-V263 loop pulls away from the active site, displacing the polypyrrole chain by about 5 Å, dragging the C1 and C2 pyrroles into a new pocket (expansion of the rear sub-cavity, orange in Figures 4B-D) ; while the S1
and S2 units now occupy the positions the cofactor had in the E holo structure, with the S1-S2 pyrrole units in ES 2 PBGD adopting exactly the same conformation and being stabilized by the same residues as the C1-C2 cofactor in E holo PBGD. This suggests that the cofactor in E holo is strongly bound and already adopts a catalytically relevant conformation. These observations are consistent with the large number of conserved surrounding residues and with the reaction's stereospecificity (34) . Yet, the ES 2 -complex is further stabilized by the extra interactions that the newly displaced C1-C2 cofactor creates with the protein at the rear cavity, mostly with T102, V215 and S262. Such added interactions provide a structural rationale for the empirical observation that ES 2 is the most stable of the purified reaction intermediates (27, 35) .
In the ES 2 -complex, D99, a key residue in the polypyrrole chain elongation, retains the hydrogen bonding with the N-H of S2 (C2 in E holo ), required for the elongation reaction, but it also falls at a reactive distance from the C2-S1 interface (3.8 Å to the S1 H-N), which is the product cleavage point (Fig. 4E-F) . This proximity strongly suggests that D99 may also play a relevant role in the product release by catalyzing the hydrolysis reaction, in agreement with the spontaneous formation of E holo when apoPBGD is incubated with HMB (36). In the context of our ES 2 PBGD structure, D99 is located at about 8.5 Å from the cofactor C1 ring (Fig. 4F) , which now would become protected from hydrolysis during the elongation process.
In E holo the active site is large (674 Å 3 , Fig. 4A ) and rich in positively charged residues (mainly Lys and Arg residues) to compensate-for and attract the negative charges introduced with the ligands' carboxylates during the elongation process. The placement of the cofactor and the location of D99 suggest that the PBG substrate enters the site from the frontal sub-cavity, as indicated by the arrow in Figure 3A . Remarkably, the displacement of the R255-V263 loop in the ES 2 PBGD intermediate enlarges the overall cavity size to a final volume of 787 Å 3 (Fig. 4D) , creating a large empty space on the distal end of the catalytic site and dividing the cavity in two similar subspaces around D99: the frontal sub-cavity that remains largely unaltered as compared to E holo (purple in Figures 4C,D , ES 2 frontal subcavity volume is 487 Å 3 ); and the rear sub-cavity (orange in Figures 4C,D) , which is very large for ES 2 (300 Å 3 ) and directly produced by the loop displacement.
To investigate which parts of the cavity are relevant for the elongation reaction, we have used a set of competitive inhibitors that are able to effectively block the reaction (K i ≤ 100 µM). Specifically, computational docking of the inhibitors into the E holo and ES 2 structures allows pinpointing the areas that may accommodate the substrate. As is shown in Fig. S6 , both sub-cavities are occupied by the inhibitors in ES 2 , while only the frontal sub-cavity is hit by the inhibitors in E holo . This is consistent with substrates approaching the active site via the frontal sub-cavity. Interestingly, the extended size of the rear sub-cavity in ES 2 would allow the tetrapyrrole to adopt a different placement, in which the S2 moiety would occupy the S1 pocket and the S1 pyrrole ring would be completely inserted into the rear sub-cavity. Such a conformation would ease the entrance to the S2 site of a subsequent PBG molecule which would then proceed to fuse with ES 2 and elongate the product to ES 3 . Based on this hypothesis, a computationally-derived model of the resulting ES 3 complex is shown in Fig.   S7 . Presumably, further displacement of the R255-V263 loop would enlarge the rear subcavity even more so the reaction can progress towards the formation of ES 4 . In support of this model, the R26H mutant located in the frontal volume has been associated only with a reduced capacity to incorporate new substrate units (34) .
The active-site loop is a lid for the catalytic site. The active site is partially protected by a flap region constituted by residues 57-74 in human PBGD, which is likely relevant in binding the substrate and cofactor as well as in aiding catalysis. This active-site loop is missing in all the deposited structures so far except in the E holo PBGD from A. thaliana (4HTG) (17) . In this structure one of two chains in the asymmetric unit of the ES 2 -complex crystal (5M6R_A) displays ordered electron density for the flap region. The latter was revealed to form a caplike structure that covers the active site. The loop in the remaining human holo-structures described so far is only partially ordered, with residues G60-I71 adopting α-helical secondary structure, while the equivalent region in PBGD ID 4HTG is much more disordered (Fig. 3C) . Interestingly, the loop in our ES 2 human structure folds towards the active site, so that residue E73 is able to form a hydrogen bond with the propionate side chain of the C2 ring of the growing product, ultimately stabilizing the complex. In the A. thaliana structure, the equivalent residue to E73 is D66, which is solvent exposed and displays no interactions, in agreement with the E holo contents of that active site.
Discussion
In this contribution, we report the first crystal structure of a reaction intermediate for PBGD
(ES 2 of human PBGD1, PBD ID 5M6R). The combined analysis of the ES 2-complex with the structure of human E holo PBGD2 (PBD ID 5M7F, also presented here) reveals that the structural changes upon polypyrrole elongation are largely constrained to the R255-V263
loop, refuting the hypothesis of significant domain rearrangements during the reaction progression up to the ES 2 intermediate (Fig. 3) . It is entirely plausible that the only significant changes in the structure during the second part of the reaction (formation of ES 4 and product release) would also only affect to the R255-V263 loop, in keeping with our SAXS, NMR and gel filtration chromatography data.
In spite of the limited extent of the reported conformational changes among the reaction intermediates, the progressive increase in the electrophoretic mobility observed in the native polyacrylamide electrophoresis (Fig. 1) and their successful ionic exchange separation (Fig.   S2 ) suggest a gradual increase in net negative charge compared to that of E apo or E holo , as previously suggested (37) . As shown in Table S1 , this is actually the case, and it can be mainly attributed to the PBGD Arg residues, which experience a large reduction in their solvent accessible area in ES 2 as compared to E holo , due to salt-bridge interactions with the negatively charged pyrrole units.
The structures reported here provide molecular detail on how the reaction process takes place within the confines of a single active site. At least three novel observations obtained from the structures appear to be relevant for the reaction mechanism: i) the displacement of the R255-V263 loop, which allows reaction progression up to the ES 2 stage, allocating the cofactor (C1-C2 rings) into a new pocket and extracting it from the catalytic pocket; ii) the displacement of the same loop generates a new internal cavity, which is potentially suitable for hosting the further reaction intermediate; and iii) the relative position of the ligands from the catalytic residue D99 (38) , which is always at reactive distance from the S2(C2) elongation pocket, but also close enough to the C2 ring. Therefore, we propose that D99 is also responsible for product release. A scheme that subsumes all these features into a mechanistic model of reaction progression is shown in Fig. 5 . In the E holo structure, the catalytic site is nearby the key residue D99 and occupied by the cofactor. The entrance of new PBG molecules occurs through the frontal sub-cavity and is facilitated by electrostatic complementarity. The entrance of the PBG into the rear sub-cavity likely produces the cofactor shift, mediated by the displacement of the loop containing Cys261. As a result, C1
now occupies a new pocket whilst C2 occupies the former C1 position and the new pyrrole unit is allocated at the condensation catalytic site. The progressive enlargement of the rear sub-cavity produced by the concerted R255-V263 loop displacement would allow for this mechanism to be repeated twice, up to the formation of the ES 4 intermediate.
A plausible mechanism for the HMB release is also shown in Fig. 5 . According to our model, cleavage of the bilane attached to the cofactor and polypyrrole elongation are catalyzed by the same aspartic acid, which is always at reactive distance from the catalytic pocket (the location of the next PBG unit for condensation) and from the N-H of C2 (likely, the cleavage point in the polymer). We hypothesize that steric tension and the proximity of the C2 ring to D99 may trigger the cleavage hydrolytic reaction and product release. Essentially, the mechanism we propose corresponds to the reverse condensation reaction mechanism, also involving an azafulvene intermediate. In this context, both reactions are reversible and they could spontaneously occur at the appropriate stage of the elongation reaction. The interplay between the two opposite reactions (condensation and hydrolysis) is governed by a delicate balance between the S2 and C2 distances to D99. According to this hypothesis, the condensation reaction would dominate from E holo to ES 4 due to a closer distance of D99 to the reaction site than to C2 (confirmed for ES 2 : D99 is at 2.2 Å and 3.8 Å of the N-H of S2
and C2 respectively), with some aid from the chemical driving force of the substrate excess.
During the elongation reaction, it is plausible that the D99(O)-C2(NH) distance shortens to favor the hydrolysis reaction, as reflected in the structural model for the ES 3 reaction intermediate (Fig. S7 ). This feature, combined with the increasing steric tension of the reaction intermediate, may favor the hydrolysis reaction. The active site loop (residues 57-74 in the human isoform) is forming a contact with the C2 ring that could presumably fine tune the distance between D99 and the pyrrole unit. The experimental reconstitution of E holo starting from E apo and HMB (36) supports this model.
The reported structures also rationalize the relative stability of the reaction intermediates.
Clearly, ES 2 is more stable than E holo , because it integrally maintains the same cofactorprotein interactions as observed in E holo , whilst being further stabilized by the interactions generated between the C1/C2 pyrroles and the residues lining the new pocket. Consistent with these observations, the ES reaction intermediate would be more stable than E holo and less stable than ES 2 . We predict that progression from ES 2 to ES 4 might generate further interactions between the polypyrrole and the cavity residues but likely at the cost of generating a tensioned and, therefore, ultimately unstable conformation.
Last but not least, the reported structures and the proposed reaction mechanism for the first time explain missense mutations in human HMBS that result in AIP. As it is common in porphyria (21), most of the 168 missense mutations reported in the Human Mutation Database (5) can be associated with reduced protein stability. Yet, a subset of the point mutations has already been associated to a loss of interactions between protein residues and the C1-C2 pyrrole units in the E holo structure, affecting the stability of the reaction intermediates (10, 39). Here we highlight the relevance of the sliding loop, key for reaction elongation, which also contains seven residues (E250, A252, L254, H256, E258, G260 and C261) that cause AIP upon mutation. It is likely that these mutations constrain the loop mobility, ultimately compromising reaction progression. Furthermore, the V215M and V215E
mutations, which would abrogate the V215-mediated stabilization of the C2 ring at the shifted position in the ES 2 structure, also result in AIP. Other residues in the rear cavity are also involved in AIP upon mutation: L254, R149, A214 and Y213. These mutants may be amenable to stabilization by pharmacological chaperones, opening new therapeutic intervention avenues against the disease. Distances between the catalytic residue D99 and some atoms relevant for the reaction are shown in (G) and (H) for E holo and ES 2 -complex. 
